Log In
Print
BCIQ
Print
Print this Print this
 

CEP-37440

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionAnaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK) inhibitor
Molecular Target Anaplastic lymphoma kinase (ALK) ; Focal adhesion kinase (FAK)
Mechanism of ActionAnaplastic lymphoma kinase (Ki-1) (ALK) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced or metastatic solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today